Wednesday, May 13, 2020 9:44:56 AM
Recent AIM News
- Form PREC14A - Preliminary proxy statements, contested solicitations • Edgar (US Regulatory) • 10/18/2024 08:34:17 PM
- Form PREC14A - Preliminary proxy statements, contested solicitations • Edgar (US Regulatory) • 10/15/2024 08:33:31 PM
- AIM ImmunoTech to Participate in the 2024 Healthcare Virtual Summit, Presented by Maxim Group LLC • GlobeNewswire Inc. • 10/09/2024 01:00:00 PM
- AIM ImmunoTech Granted U.S. Patent for Ampligen® for the Treatment of Endometriosis • GlobeNewswire Inc. • 10/03/2024 12:45:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/01/2024 07:55:19 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 10/01/2024 05:12:28 PM
- AIM ImmunoTech Announces Pricing of $1.26 Million Registered Direct Offering • GlobeNewswire Inc. • 09/30/2024 01:00:00 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 09/30/2024 12:22:43 PM
- AIM ImmunoTech to Participate in Virtual Investor CEO Connect Segment • GlobeNewswire Inc. • 09/27/2024 12:00:00 PM
- AIM ImmunoTech Reports Positive Preliminary Data in Phase 1b/2 Study of Ampligen and Imfinzi as a Combination Therapy for Late-Stage Pancreatic Cancer • GlobeNewswire Inc. • 09/19/2024 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/17/2024 04:05:17 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/16/2024 07:45:11 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/12/2024 09:15:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/12/2024 08:45:37 PM
- Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend] • Edgar (US Regulatory) • 09/11/2024 09:40:58 PM
- AIM ImmunoTech Announces that Analysis of AMP-518 Complete Clinical Patient Data Underscores Ampligen’s Potential to Improve the Post-COVID Condition of Fatigue • GlobeNewswire Inc. • 09/11/2024 01:00:00 PM
- Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend] • Edgar (US Regulatory) • 09/04/2024 01:43:58 AM
- AIM ImmunoTech Announces Print Publication and Further Positive Findings from a Study Evaluating Ampligen® in the Treatment of Pancreatic Cancer in the Journal Clinical Cancer Research • GlobeNewswire Inc. • 08/20/2024 12:30:00 PM
- AIM ImmunoTech Reports Second Quarter 2024 Financial Results and Provides Corporate Update • GlobeNewswire Inc. • 08/16/2024 11:00:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2024 09:00:56 PM
- Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend] • Edgar (US Regulatory) • 08/14/2024 11:37:57 AM
- AIM ImmunoTech to Discuss Second Quarter 2024 Financial Results on August 16, 2024, and Host Conference Call and Webcast • GlobeNewswire Inc. • 08/13/2024 01:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/13/2024 01:41:02 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/13/2024 01:39:11 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/01/2024 10:05:15 AM
SANUWAVE Announces Reverse Stock Split, Note and Warrant Exchange, and PIPE Offering • SNWV • Oct 18, 2024 9:31 AM
Vocodia Addresses Recent Stock Price Movement and Future Strategic Partnerships • VHAI • Oct 18, 2024 9:00 AM
Mass Megawatts Announces the Start of an Online Discount Solar Energy Equipment Business with Revenue Recognized for the First Time Since Year 2010 in this Fiscal Quarter • MMMW • Oct 18, 2024 7:32 AM
Unitronix Corp Advances DeFi Innovation with Tokenized Real-World Assets Integration • UTRX • Oct 17, 2024 7:38 AM
Mass Megawatts Commences Solar Energy Sales Efforts • MMMW • Oct 16, 2024 7:45 AM
SANUWAVE Health Announces 1-For-375 Reverse Stock Split • SNWV • Oct 16, 2024 7:40 AM